Related references
Note: Only part of the references are listed.Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
Paul D. P. Pharoah et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Yusuke Nakamura et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 198 Trial
Vincent Stanto
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients
James M. Rae et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Tamoxifen and CYP2D6: A Contradiction of Data
Daniel L. Hertz et al.
ONCOLOGIST (2012)
CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark
Timothy L. Lash et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Concordance of metabolic enzyme genotypes assayed from paraffin-embedded, formalin-fixed breast tumors and normal lymphatic tissue
Thomas Ahern
Clinical Epidemiology (2010)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Genotyping for polymorphic drug metabolizing enzymes from paraffin-embedded and immunohistochemically stained tumor samples
JM Rae et al.
PHARMACOGENETICS (2003)
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
LD Bradford
PHARMACOGENOMICS (2002)
Share Paper
